Anakinra
Anakinra is a recombinant interleukin-1 receptor antagonist (IL-1Ra).
It is used to reduce inflammation in rheumatoid arthritis, Still’s disease, and rare autoinflammatory conditions.
By blocking IL-1–mediated pathways, it slows disease progression, reduces joint damage, and alleviates systemic inflammation.
Always check the BNF link here for the latest prescribing advice.
⚙️ Mechanism of Action
- Competitive antagonist at the IL-1 receptor, blocking IL-1α and IL-1β signalling.
- Inhibits downstream cytokine cascades → ↓ neutrophil recruitment, ↓ synovial inflammation.
- Clinically improves pain, swelling, and prevents radiographic progression of joint disease.
💊 Dose Range (Confirm with BNF or product SPC)
| Indication |
Details |
| 🦴 Rheumatoid Arthritis |
Anakinra
• 100 mg SC injection OD
|
| 🧒 Still’s Disease (incl. systemic JIA & AOSD) |
Anakinra
• Adults: 100 mg SC injection OD
• Children: Weight-based dosing
|
| 🔥 Other Autoinflammatory Syndromes (e.g. CAPS, FMF) |
Anakinra
• Variable specialist dosing
• Usually OD, may ↑ to BD in severe disease
|
⚠️ Cautions & Contraindications
- Active or recurrent infections (risk of sepsis).
- Neutropenia — check baseline and monitor regularly; avoid if neutrophils very low.
- Asthma — higher risk of hypersensitivity reactions.
- Renal impairment — mainly renally excreted; accumulation possible if eGFR < 30 mL/min.
- Avoid use with TNF-α inhibitors (markedly ↑ infection risk).
- Screen for latent TB and hepatitis before initiation.
🧪 Monitoring
- Baseline and regular FBC (esp. neutrophils, platelets).
- Renal function (adjust dose if severe impairment).
- Monitor for infection symptoms throughout therapy.
⚠️ Side Effects
- Very common: injection site reactions (pain, erythema, swelling).
- Headache, nausea, diarrhoea.
- Infections: URTIs, cellulitis, pneumonia.
- Haematological: neutropenia, thrombocytopenia.
- Rare: hypersensitivity, anaphylaxis, liver enzyme elevation.
📚 References
- BNF: Anakinra
- MHRA / EMA Summary of Product Characteristics (SPC)